BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical Company focused on oncology, today announced results from the triple combination arm of the Company’s COMBAT/KEYNOTE-202 clinical study evaluating motixafortide (BL-8040) in combination with KEYTRUDA┬« (pembrolizumab) and chemotherapy in patients with second-line stage IV pancreatic ductal adenocarcinoma (PDAC). Company reports a Substantial improvement observed across all study endpoints, including overall survival, progression free survival and overall response rate, in the most challenging PDAC patients. Company plans to meet with regulatory authorities as it evaluates next development steps.